Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Cytori Provides Business Update Along with Top-line Unaudited 2014 Financial Results at the Cowen and Company 35th Annual Health Care Conference in Boston

Business Wire March 4, 2015

Cytori to Provide Corporate Update at Cowen and Company 35th Annual Health Care Conference

Business Wire March 3, 2015

FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites

Business Wire February 26, 2015

Cytori Receives Positive European Opinion on Orphan Drug Status

Business Wire February 24, 2015

Cytori Begins Enrollment in ACT-OA: US Phase II Trial for Knee Osteoarthritis

Business Wire February 17, 2015

Enrollment Begins European Knee Meniscus Injury Pilot Trial to Evaluate Cytori Cell Therapy

Business Wire February 10, 2015

Cytori and Leading Expert Discuss Importance of 'STAR' Trial and Treatment for Scleroderma Patients

Business Wire January 20, 2015

FDA Approves Cytori U.S. Pivotal Scleroderma Trial

Business Wire January 12, 2015

Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury Countermeasure

Business Wire December 19, 2014

Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal Investigator, Dr. Dinesh Khanna

Business Wire December 18, 2014

Cytori to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco

Business Wire December 17, 2014

FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma

Business Wire December 10, 2014

Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing

Canada NewsWire December 5, 2014

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com

Canada NewsWire December 2, 2014

Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with Anterior Cruciate Ligament Repair

Business Wire November 21, 2014

Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast

Canada NewsWire November 20, 2014

Safety and Feasibility of Cytori Cell Therapy in Acute Myocardial Infarction Presented at 2014 American Heart Association Meeting

Business Wire November 18, 2014

Cytori Reports Third Quarter 2014 Business and Financial Results

Business Wire November 6, 2014

Cytori to Webcast Third Quarter Financial Results on November 6

Business Wire October 24, 2014

Cytori Therapeutics Receives FDA Approval to Resume ATHENA Trial Enrollment

Business Wire October 22, 2014